gb1211

Small moleculeexperimental

Clinical trial activity

7 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
6
Phase 2
4
Phase 3
0
Phase 4
0

Earliest trial started Jan 14, 2019 (NCT03809052)

Timeline

2010s

  1. Jan 1, 2019

    Earliest Phase 1 Sponsor(trial)

2020s

  1. Jan 1, 2023

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

OC[C@H]1O[C@H](Sc2cncc(Br)c2)[C@H](O)[C@@H](n2cc(-c3cc(F)c(F)c(F)c3)nn2)[C@H]1O
Mol. weight
533.33 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07082270Phase 1Feb 1, 2026State University of New York, Buffalo
NCT05913388Phase 2Dec 31, 2023Galecto Biotech, Providence Health & Services
NCT05747573Phase 1Jan 3, 2023Galecto Biotech, QPS
NCT05240131Phase 1/Phase 2 (Phase 2)Mar 15, 2022Galecto Biotech, Roche
NCT05009680Phase 1/Phase 2 (Phase 2)Sep 9, 2021Comac Medical, Galecto Biotech
NCT04607655Phase 1/Phase 2 (Phase 2)Mar 31, 2021Covance, Galecto Biotech, University of Chicago
NCT03809052Phase 1Jan 14, 2019Covance, Galecto Biotech
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Galecto BiotechFor profit6522019
CovanceFor profit2022019
Comac MedicalFor profit1012021
Providence Health & ServicesAcademic/Hospital1112023
QPSFor profit1012023
RocheFor profit1012022
State University of New York, BuffaloAcademic/Hospital1112026
University of ChicagoAcademic/Hospital1012021
8 organizations
Page 1 / 1